SEC Form 4 · accession 0001140361-17-025622
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
V Bryan Lawlis
Director
Period of report
Jun 16, 2017
Accepted (ET)
Jun 20, 2017 · 6:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 16, 2017 | M | 3,750 | $38.59 | A | 19,660 | D | |
| Common StockF1,F2 | Jun 16, 2017 | S | 3,750 | $90.00 | D | 15,910 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) Common StockF1,F3 | $38.59 | Jun 16, 2017 | M | 3,750 | D | Aug 22, 2008 | May 21, 2018 | Common Stock | 3,750 | 11,250 | D |
Explanation of responses
- F1Trade made pursuant to a 10b5-1 plan executed on May 9, 2017
- F2All shares sold at the same price.
- F3Reflects the number of stock options outstanding after the transaction from this specific stock option grant.